Loading...
•
Mar 31, 2021
Cassava Sciences Q1 2021 Earnings Report
Reported financial results for the first quarter ended March 31, 2021 and provided guidance regarding the release of new clinical data with simufilam.
Key Takeaways
Cassava Sciences reported a net loss of $3.5 million, or $0.09 per share, for the first quarter of 2021. Cash and cash equivalents were $282.2 million as of March 31, 2021.
9-Month Interim Analysis of Open-label Study to be Presented at a Major Scientific Conference in July 2021 as an Oral Presentation.
Initiation of Pivotal Phase 3 Program Remains On-track for 2nd Half 2021.
Initiation of Cognition Maintenance Study On-track for June 2021.
Cash and cash equivalents were $282.2 million at March 31, 2021.
Cassava Sciences
Cassava Sciences
Forward Guidance
Net cash use for operations for full-year 2021 is expected to be approximately $20 to $25 million.